GREY:IMVIF - Post by User
Post by
alphaseeking001on Jan 20, 2020 8:05pm
161 Views
Post# 30575607
How advanced to we have to be to be considered for buyout?
How advanced to we have to be to be considered for buyout?Qwerty22 and QM45 thanks again for two well thought out recent postings. I agree with Qwerty that we have to be measured in our thinking and not get too excited about potential endgames (although I'm sure QM45 wasn't implying that any type of buyout was imminent, just that eventually, IMV could work towards such a goal as those other recent buyouts) but it is helpful to have a bigger picture of where IMV could move if the clinical program continues to look good.
My question is hypothetical of course but at what point in these clinical milestones might we actually be considered by larger biotechs in a potential buyout? How much further do we have to go? Obviously it could take another couple of years to really flush out all the clinical trials ongoing or getting started... are we expecting that IMV will remain independent through those years? Or do we expect they would be considered a target before then? Any thoughts will be much appreciated as usual. It's been a tough road with IMV keeping an even keel between excitement (and at times despair!)
Cheers